Literature DB >> 25707506

Role of tumor-associated macrophages in hematological malignancies.

Yoshihiro Komohara1, Daisuke Niino, Koji Ohnishi, Koichi Ohshima, Motohiro Takeya.   

Abstract

The tumor microenvironment consists of many non-tumor cells such as leukocytes, endothelial cells, and fibroblasts, and phenotypic changes in a tumor microenvironment are believed to be involved in tumor progression and resistance to anticancer treatments. In hematological malignancies, tumor-associated macrophages (TAMs) that have infiltrated lymphoma or leukemia tissues may be involved in tumor progression, and many researchers have studied phenotypic changes in TAMs. This review article summarizes the publications related to TAMs in hematological malignancies, with an emphasis on CD163(+) protumoral TAMs, which seem to be associated with disease progression. Cell-cell interactions between protumoral TAMs and lymphoma or leukemia cells may play an important role in lymphoma or leukemia microenvironments. Although detailed molecular mechanisms of these cell-cell interactions have not yet been clarified, phenotypic characterization of TAMs is thought to be a useful approach for evaluating clinical prognosis. In addition, targeting TAMs may be a new strategy for treating malignant hematological diseases.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  CD163; CD204; TAM; leukemia-lymphoma; macrophage; tumor microenvironment

Mesh:

Year:  2015        PMID: 25707506     DOI: 10.1111/pin.12259

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  38 in total

1.  Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.

Authors:  Tadahiko Yanagita; Yoji Murata; Daisuke Tanaka; Sei-Ichiro Motegi; Eri Arai; Edwin Widyanto Daniwijaya; Daisuke Hazama; Ken Washio; Yasuyuki Saito; Takenori Kotani; Hiroshi Ohnishi; Per-Arne Oldenborg; Noel Verjan Garcia; Masayuki Miyasaka; Osamu Ishikawa; Yae Kanai; Takahide Komori; Takashi Matozaki
Journal:  JCI Insight       Date:  2017-01-12

2.  Selective depletion of cultured macrophages by magnetite nanoparticles modified with gelatin.

Authors:  Yoshihiro Komohara; Ryuta Kawauchi; Erika Makiyama; Kazuki Mikami; Hasita Horlad; Yukio Fujiwara; Tetsuya Kida; Motohiro Takeya; Takuro Niidome
Journal:  Exp Ther Med       Date:  2017-06-21       Impact factor: 2.447

Review 3.  Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Authors:  Emily M Hsieh; Rayne H Rouce
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.

Authors:  Elias D Bührer; Michael A Amrein; Stefan Forster; Stephan Isringhausen; Christian M Schürch; Salil S Bhate; Tess Brodie; Joel Zindel; Deborah Stroka; Mohamad Al Sayed; César Nombela-Arrieta; Ramin Radpour; Carsten Riether; Adrian F Ochsenbein
Journal:  Leukemia       Date:  2022-09-26       Impact factor: 12.883

5.  TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma.

Authors:  Hasita Horlad; Koji Ohnishi; Chaoya Ma; Yukio Fujiwara; Daisuke Niino; Koichi Ohshima; Masahisa Jinushi; Masao Matsuoka; Motohiro Takeya; Yoshihiro Komohara
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

6.  Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth.

Authors:  Xiaolan Yu; Jingfeng Sha; Shao Xiang; Sanhai Qin; Patricia Conrad; Santosh K Ghosh; Aaron Weinberg; Fengchun Ye
Journal:  Cell Cycle       Date:  2016-06-13       Impact factor: 4.534

7.  Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.

Authors:  Mollie E Barnard; Jonathan L Hecht; Megan S Rice; Mamta Gupta; Holly R Harris; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-30       Impact factor: 4.254

8.  Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

Authors:  C A Gomez-Roca; A Italiano; C Le Tourneau; P A Cassier; M Toulmonde; S P D'Angelo; M Campone; K L Weber; D Loirat; M A Cannarile; A-M Jegg; C Ries; R Christen; G Meneses-Lorente; W Jacob; I Klaman; C-H Ooi; C Watson; K Wonde; B Reis; F Michielin; D Rüttinger; J-P Delord; J-Y Blay
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

Review 9.  Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Authors:  Ya Zhang; Xin Wang; Zixun Yin
Journal:  Biomark Res       Date:  2021-07-13

Review 10.  Immune checkpoint inhibitors in lymphoma: challenges and opportunities.

Authors:  Haris Hatic; Devi Sampat; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.